A comprehensive view of Diabetes. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Consumer Wellness Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Eli Lilly and Boehringer Ingelheim report diabetes drug Jardiance empagliflozin significantly reduced average blood sugar in children, adolescents with type 2 diabetes in a late-stage study

State of Kansas files lawsuit alleging Sanofi-Aventis, Eli Lilly, Novo Nordisk and middlemen conspired to drive up insulin prices; lawsuit alleges that insulin selling for US$300 to US$700 cost less than US$5 to make

India approves AstraZeneca’s Dapagliflozin for diabetes patients with chronic kidney disease; the drug significantly reduces risk of sustained estimated glomerular filtration rate, cardiovascular deaths, hospitalizations due to heart failure

Global drug delivery devices market expected to hit US$124.8B by 2029, with CAGR growth of 5.6% from 2022-2029 driven by increase in chronic diseases, including diabetes; diabetes expected to affect 783 million people worldwide by 2045

GlobalData: Continuous glucose monitoring devices could become main solution for US diabetes population if FDA's proposed changes to reimbursement go ahead; majority of diabetes patients currently have to undergo invasive self-testing several times a day

Ask us about our Consumer Wellness market view

Trending Chart

Interactive chart with headline count